Loading…
Please register to continue your trial period!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Interim results have been reported for 48 subjects who received the combination of pembrolizumab and DNX-2401 and achieved a median overall survival of 12 months; 47% experienced a clinical benefit (stable disease or better). In detail, four subjects had partial responses, two of whom showed 94% regression of tumor volume and three survived for more than 20 months [64] (Hwang et al. 2020a)
see also:
Oncolytic viruses & Glioblastoma multiforme (GBM) / Glioblastoma
…